India is set for a major shift as the patent on semaglutide—used in Ozempic and Wegovy by Novo Nordisk- expires on 20 March 2026. - BBC (19 March 2026)
This is expected to trigger a surge of cheaper branded generics, potentially cutting monthly costs by more than half and expanding access.
Major Indian drugmakers are preparing launches, targeting a fast-growing obesity and diabetes market.
While wider availability could transform care, experts warn of misuse, side effects and the need for proper clinical oversight. Regulators are tightening controls on marketing as India balances improved access with safety, prescribing discipline, and growing global export opportunities.